Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study.
Zhichao Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Deng(Center for Excellence in Brain Science and Intelligence Technology), Yunbo Zhao(University of Science and Technology of China), Lin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wen Zhang(Xidian University), Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 2
Related Papers
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
|Biochemical Pharmacology|2020|160
Bim and Noxa Are Candidates to Mediate the Deleterious Effect of the NF-κB Subunit RelA in Cerebral Ischemia
|Journal of Neuroscience|2006|135
PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain
|Current Pharmaceutical Design|2017|126
The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
|Biological Trace Element Research|1997|122